JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

NCT06852391 on ClinicalTrials.gov · last registry update 2026-01-14

Recruiting now, toward 74 participants. Due to report 31 December 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Measurement of Adaptive thermogenesis. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: McMaster University
Sponsor type: Other
Enrollment: 74
Started: 2025-06-18
Primary completion: 2027-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Measurement of Adaptive thermogenesis

Conditions studied

Obesity (Disorder)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.